COMMUNIQUÉS West-GlobeNewswire

-
PolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in Poland
11/03/2024 -
PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock Market
11/03/2024 -
PHAXIAM Therapeutics annonce la réalisation du retrait volontaire de ses « American Depository Shares » du Nasdaq Stock Market
11/03/2024 -
Press Release: New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
11/03/2024 -
Communiqué de presse : De nouveaux résultats de phase II relatifs à l’amlitelimab confortent son potentiel de meilleur médicament de sa catégorie en termes de maintien de la réponse dans le traitement de la dermatite atopique
11/03/2024 -
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
11/03/2024 -
Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting
10/03/2024 -
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
10/03/2024 -
New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction
09/03/2024 -
Alumis Presents Positive Data from Phase 2 Clinical Trial of ESK-001, an Oral Allosteric TYK2 Inhibitor for the Treatment of Plaque Psoriasis, at AAD Annual Meeting
09/03/2024 -
Samsung Bioepis Presents Two Abstracts for Its Immunology Portfolio at the 2024 American Academy of Dermatology (AAD) Annual Meeting
09/03/2024 -
Ultimovacs ASA: Mandatory notification of trades by primary insider
09/03/2024 -
Aesthetic Medical International Holdings Group Ltd. Announces Receipt of a Letter of Expected Delisting Determination From Nasdaq Staff and Intention to Request a Hearing before the Nasdaq Hearings Panel
08/03/2024 -
Confluent Appoints Sandy Stojkovski and Brian Yoor to its Board of Directors
08/03/2024 -
Ultimovacs ASA: Mandatory notification of trades by primary insider
08/03/2024 -
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/03/2024 -
PharmAla Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update
08/03/2024 -
Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
08/03/2024 -
Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/03/2024
Pages